文献速递头痛与眩晕

偏头痛女性的性激素与降钙素基因相关肽:一项横断面匹配队列研究

Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study.
PubMed 文献 · Neurology · 2023-02-22

本研究纳入180例女性(每组30例),比较发作性偏头痛(EM)伴规律月经周期(RMC)、EM使用复方口服避孕药(COC)、绝经后EM女性与年龄匹配无EM对照组的血浆和泪液降钙素基因相关肽(CGRP)浓度。结果显示,伴RMC的EM女性月经期血浆和泪液CGRP均显著高于无偏头痛女性;COC组和绝经后组中偏头痛与对照组CGRP水平相似。伴RMC的EM女性月经期泪液CGRP显著高于COC组。

要点

  • 伴规律月经周期的发作性偏头痛女性,月经期血浆CGRP为5.95 pg/mL(IQR 4.37-10.44),高于无偏头痛女性的4.61 pg/mL(IQR 2.83-6.92),p=0.020。
  • 伴规律月经周期的发作性偏头痛女性,月经期泪液CGRP为1.20 ng/mL(IQR 0.36-2.52),高于无偏头痛女性的0.4 ng/mL(IQR 0.14-1.22),p=0.005。
  • 使用复方口服避孕药的偏头痛女性和绝经后偏头痛女性,其CGRP水平与相应对照组相似。

核心结论

  • 不同的性激素谱可能影响有当前或既往月经能力的偏头痛患者的CGRP浓度。
  • 泪液CGRP测量可行,值得进一步研究。

研究设计与样本

  • 横断面、匹配队列研究,共纳入180例女性参与者,每组30例。
  • 分组包括:发作性偏头痛伴规律月经周期女性、发作性偏头痛使用复方口服避孕药女性、绝经后发作性偏头痛女性,以及3组年龄匹配的无发作性偏头痛女性对照。
  • 规律月经周期参与者于月经周期第2±2天(月经期)和第13±2天(围排卵期)各访视一次。
  • 复方口服避孕药使用者在无激素间期第4±2天和激素摄入第7至14天之间接受检查。
  • 绝经后参与者在随机时间点评估一次。

主要发现

  • 伴规律月经周期的偏头痛女性月经期血浆CGRP为5.95 pg/mL(IQR 4.37-10.44),无偏头痛女性为4.61 pg/mL(IQR 2.83-6.92),p=0.020(Mann-Whitney U检验)。
  • 伴规律月经周期的偏头痛女性月经期泪液CGRP为1.20 ng/mL(IQR 0.36-2.52),无偏头痛女性为0.4 ng/mL(IQR 0.14-1.22),p=0.005(Mann-Whitney U检验)。
  • 使用复方口服避孕药的偏头痛女性与相应对照组CGRP水平相似,绝经后偏头痛女性与相应对照组CGRP水平相似。
  • 伴规律月经周期的偏头痛女性月经期泪液CGRP显著高于使用复方口服避孕药的偏头痛女性(无激素间期p=0.015,激素摄入期p=0.029,Mann-Whitney U检验),而血浆CGRP无此差异。

局限性

  • 原文结论指出泪液CGRP测量可行,值得进一步研究(warrants further investigation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Sex hormones may modulate calcitonin gene-related peptide (CGRP) release in the trigeminovascular system. We studied CGRP concentrations in plasma and tear fluid in female participants with episodic migraine (EM) and a regular menstrual cycle (RMC), female participants with EM and combined oral contraception (COC), and female participants with EM in the postmenopause. For control, we analyzed 3 corresponding groups of age-matched female participants without EM. METHODS: Participants with an RMC had 2 visits: during menstruation on menstrual cycle day 2 ± 2 and in the periovulatory period on day 13 ± 2. Participants with COC were examined at day 4 ± 2 of the hormone-free interval (HFI) and between days 7 and 14 of hormone intake (HI). Postmenopausal participants were assessed once at a random time point. Plasma and tear fluid samples were collected at each visit for determination of CGRP levels with an ELISA. RESULTS: A total of 180 female participants (n = 30 per group) completed the study. Participants with migraine and an RMC showed statistically significantly higher CGRP concentrations in plasma and tear fluid during menstruation compared with female participants without migraine (plasma: 5.95 pg/mL [IQR 4.37-10.44] vs 4.61 pg/mL [IQR 2.83-6.92], p = 0.020 [Mann-Whitney U test]; tear fluid: 1.20 ng/mL [IQR 0.36-2.52] vs 0.4 ng/mL [IQR 0.14-1.22], p = 0.005 [Mann-Whitney U test]). In contrast, female participants with COC and in the postmenopause had similar CGRP levels in the migraine and the control groups. In migraine participants with an RMC, tear fluid but not plasma CGRP concentrations during menstruation were statistically significantly higher compared with migraine participants under COC (p = 0.015 vs HFI and p = 0.029 vs HI, Mann-Whitney U test). DISCUSSION: Different sex hormone profiles may influence CGRP concentrations in people, with current or past capacity to menstruate, with migraine. Measurement of CGRP in tear fluid was feasible and warrants further investigation.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Raffaelli B, Storch E, Overeem LH, et al. Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023. PMID: 36813730. doi:10.1212/WNL.0000000000207114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。